My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novartis AG Common Stock (NY:NVS)

164.35 +1.68 (+1.03%)

Streaming Delayed Price Updated: 10:51 AM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health ↗

October 21, 2025

Novartis (NVS) offers a strong 3.35% dividend yield with a history of steady growth, backed by robust profitability and sound financial health for reliable income.

Via Chartmill

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial ↗

October 17, 2025

Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival.

Via Benzinga

Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug ↗

October 17, 2025

Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients.

Via Investor's Business Daily

AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution

October 16, 2025

Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is...

Via TokenRing AI

Topics Artificial Intelligence

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗

October 16, 2025

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors ↗

October 16, 2025

Novartis (NVS) is a financially sound pharma leader trading at an attractive valuation with strong profitability and steady growth.

Via Chartmill

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗

October 14, 2025

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints.

Via Benzinga

Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results

October 13, 2025

Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from...

Via MarketMinute

Topics Economy Supply Chain

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗

October 13, 2025

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Via The Motley Fool

Topics ETFs Government World Trade

JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance

October 10, 2025

JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the...

Via MarketMinute

Topics Economy Intellectual Property

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Cullen Capital Dumps 40% of BCE Holdings ↗

October 07, 2025

Via The Motley Fool

AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design

October 06, 2025

A groundbreaking advancement in artificial intelligence has opened new frontiers in understanding and designing intrinsically disordered proteins (IDPs), a class of biomolecules previously considered...

Via TokenRing AI

Topics Artificial Intelligence Derivatives

European Markets Soar: Healthcare and Mining Lead the Charge Amidst Dovish Fed and Robust Fundamentals

October 04, 2025

European financial markets are currently experiencing a period of remarkable strength, with major indices reaching or nearing all-time highs in early October 2025. This significant rally is largely...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

2 Surefire Dividend Stocks to Buy for the Long Haul ↗

October 04, 2025

Both have crushed the market in 2025.

Via The Motley Fool

Topics Economy Government Intellectual Property

Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures

October 02, 2025

A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human...

Via MarketMinute

Topics Artificial Intelligence Derivatives

Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings

October 02, 2025

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine

October 02, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in...

Via TokenRing AI

Topics Artificial Intelligence Economy

Cullen Trims KVUE Stake With $149.5M Share Sale ↗

October 01, 2025

Via The Motley Fool

Topics Regulatory Compliance

Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape

September 30, 2025

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Cullen Sells 1.4 Million Dow Shares Worth $39.7 Million Amid Steep Stock Decline ↗

September 30, 2025

Via The Motley Fool

Topics Stocks

Pharma's Direct-To-Patient Wave Hits Novartis Next ↗

September 29, 2025

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.

Via Benzinga

AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth

September 29, 2025

AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York...

Via MarketMinute

Topics Economy

Novartis AG-Sponsored ADR (NYSE:NVS): A Strong Dividend Stock with High Profitability and Sound Financial Health ↗

September 29, 2025

Novartis (NVS) offers a strong 3.58% dividend yield with a history of steady payments, supported by high profitability and sound financial health for sustainable income.

Via Chartmill

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital...

Via MarketMinute

Topics Artificial Intelligence

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' ↗

September 25, 2025

President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishings in particular, to shore up domestic industry in these sectors, and...

Via Benzinga

Topics Government World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.